Literature DB >> 21996800

Transcriptional deficits in oxidative phosphorylation with statin myopathy.

Monica J Hubal1, Kimberly A Reich, Andrea De Biase, Cherie Bilbie, Priscilla M Clarkson, Eric P Hoffman, Paul D Thompson.   

Abstract

INTRODUCTION: Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, are widely used drugs for hyperlipidemia and are generally well-tolerated, but the can produce skeletal muscle toxicity. The molecular mechanisms driving statin myopathy are unknown. We investigated the effects of statin treatment and eccentric (damaging) exercise on transcriptional patterns between statin myopathy (Sym; N = 9) and statin-tolerant subjects (Asym; N = 6).
METHODS: Skeletal muscle biopsies were collected 6 h post-exercise at baseline and after statin treatment. Subjects performed concentric (non-damaging) exercise with one leg and concentric + eccentric exercise with the other leg using a cross-over design between time-points.
RESULTS: Sym as compared with Asym demonstrated decreased skeletal muscle gene expression for oxidative phosphorylation-related and mitochondrial ribosomal protein genes before and after statin treatment with eccentric exercise.
CONCLUSIONS: These results suggest that pre-existing deficiencies in energy production may contribute to the development of symptoms during statin therapy, especially when muscle is exposed to eccentric exercise.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996800     DOI: 10.1002/mus.22081

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  The effects of statin medications on aerobic exercise capacity and training adaptations.

Authors:  Zsolt Murlasits; Zsolt Radák
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

2.  Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy.

Authors:  Shuang Yang; Sumita Mishra; Lijun Chen; Jian-Ying Zhou; Daniel W Chan; Subroto Chatterjee; Hui Zhang
Journal:  Anal Chem       Date:  2015-10-06       Impact factor: 6.986

Review 3.  Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes.

Authors:  Beth A Parker; Paul D Thompson
Journal:  Exerc Sport Sci Rev       Date:  2012-10       Impact factor: 6.230

Review 4.  Metabolism pathways in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Merav Barzilai; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2015-12-08

Review 5.  Statin-Associated Muscle Disease: Advances in Diagnosis and Management.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 6.  Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses.

Authors:  Mariana Rotta Bonfim; Acary Souza Bulle Oliveira; Sandra Lia do Amaral; Henrique Luiz Monteiro
Journal:  Arq Bras Cardiol       Date:  2015-02-13       Impact factor: 2.000

Review 7.  Statin-induced Myopathy in Skeletal Muscle: the Role of Exercise.

Authors:  Hyo-Bum Kwak
Journal:  J Lifestyle Med       Date:  2014-09-30

8.  Molecular mechanisms of statin intolerance.

Authors:  Anna Gluba-Brzozka; Beata Franczyk; Peter P Toth; Jacek Rysz; Maciej Banach
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

9.  Geranylgeraniol Prevents Statin-Dependent Myotoxicity in C2C12 Muscle Cells through RAP1 GTPase Prenylation and Cytoprotective Autophagy.

Authors:  Anna Jaśkiewicz; Beata Pająk; Anna Litwiniuk; Kaja Urbańska; Arkadiusz Orzechowski
Journal:  Oxid Med Cell Longev       Date:  2018-05-21       Impact factor: 6.543

10.  The Impact of Exercise on Statin-Associated Skeletal Muscle Myopathy.

Authors:  Hae R Chung; Mayand Vakil; Michael Munroe; Alay Parikh; Benjamin M Meador; Pei T Wu; Jin H Jeong; Jeffrey A Woods; Kenneth R Wilund; Marni D Boppart
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.